理解Stargardt病的遗传病理:对当前发现和挑战的回顾

IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY Expert Opinion on Orphan Drugs Pub Date : 2021-02-01 DOI:10.1080/21678707.2021.1898373
David A Camp, Michael Gemayel, T. Ciulla
{"title":"理解Stargardt病的遗传病理:对当前发现和挑战的回顾","authors":"David A Camp, Michael Gemayel, T. Ciulla","doi":"10.1080/21678707.2021.1898373","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction: Stargardt macular dystrophy (STGD1), an autosomal recessive disorder, is caused by genetic mutations affecting ATP-Binding Cassette, subfamily A, member 4 (ABCA4). The genetic pathology of STGD1 is complex. Over 1200 disease-causing ABCA4 mutations have been identified which vary in disease severity and geographic/ethnic frequency. Areas Covered: This article provides an introduction to STGD1 and its pathophysiology, including a summary of the normal visual cycle and a description of the ABCA4 protein. The current understanding of the genetic pathology of STGD1 is reviewed, including the relationship between STGD1 and similar diseases, genotype-phenotype correlations of ABCA4-associated retinopathy, types of disease-causing genetic variations, geographic/ethnic considerations, and gene therapy. Expert Opinion: In STGD1, ABCA4 gene mutations and gene variation combinations in individuals can be used to predict phenotype, and can be categorized by severity. However, some cases of STGD1 remain unsolved, and disease severity for many variants remains unknown. Increasing our understanding of the genetic pathology of Stargardt disease will drive the development of future therapies.","PeriodicalId":12118,"journal":{"name":"Expert Opinion on Orphan Drugs","volume":"9 1","pages":"35 - 44"},"PeriodicalIF":0.8000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21678707.2021.1898373","citationCount":"1","resultStr":"{\"title\":\"Understanding the genetic pathology of Stargardt disease: a review of current findings and challenges\",\"authors\":\"David A Camp, Michael Gemayel, T. Ciulla\",\"doi\":\"10.1080/21678707.2021.1898373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Introduction: Stargardt macular dystrophy (STGD1), an autosomal recessive disorder, is caused by genetic mutations affecting ATP-Binding Cassette, subfamily A, member 4 (ABCA4). The genetic pathology of STGD1 is complex. Over 1200 disease-causing ABCA4 mutations have been identified which vary in disease severity and geographic/ethnic frequency. Areas Covered: This article provides an introduction to STGD1 and its pathophysiology, including a summary of the normal visual cycle and a description of the ABCA4 protein. The current understanding of the genetic pathology of STGD1 is reviewed, including the relationship between STGD1 and similar diseases, genotype-phenotype correlations of ABCA4-associated retinopathy, types of disease-causing genetic variations, geographic/ethnic considerations, and gene therapy. Expert Opinion: In STGD1, ABCA4 gene mutations and gene variation combinations in individuals can be used to predict phenotype, and can be categorized by severity. However, some cases of STGD1 remain unsolved, and disease severity for many variants remains unknown. Increasing our understanding of the genetic pathology of Stargardt disease will drive the development of future therapies.\",\"PeriodicalId\":12118,\"journal\":{\"name\":\"Expert Opinion on Orphan Drugs\",\"volume\":\"9 1\",\"pages\":\"35 - 44\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2021-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21678707.2021.1898373\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Orphan Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21678707.2021.1898373\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Orphan Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678707.2021.1898373","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

摘要

摘要简介:Stargardt macular dystrophy (STGD1)是一种常染色体隐性遗传病,由影响atp结合盒亚家族A成员4 (ABCA4)的基因突变引起。STGD1的遗传病理是复杂的。已经确定了1200多种致病的ABCA4突变,其疾病严重程度和地理/种族频率各不相同。涵盖领域:本文介绍了STGD1及其病理生理学,包括对正常视觉周期的总结和ABCA4蛋白的描述。综述了目前对STGD1遗传病理学的认识,包括STGD1与类似疾病的关系,abca4相关视网膜病变的基因型-表型相关性,致病遗传变异的类型,地理/种族因素以及基因治疗。专家意见:在STGD1中,ABCA4基因突变和个体基因变异组合可用于预测表型,并可根据严重程度进行分类。然而,一些STGD1病例仍未得到解决,许多变异的疾病严重程度仍然未知。增加我们对Stargardt病遗传病理的理解将推动未来治疗方法的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Understanding the genetic pathology of Stargardt disease: a review of current findings and challenges
ABSTRACT Introduction: Stargardt macular dystrophy (STGD1), an autosomal recessive disorder, is caused by genetic mutations affecting ATP-Binding Cassette, subfamily A, member 4 (ABCA4). The genetic pathology of STGD1 is complex. Over 1200 disease-causing ABCA4 mutations have been identified which vary in disease severity and geographic/ethnic frequency. Areas Covered: This article provides an introduction to STGD1 and its pathophysiology, including a summary of the normal visual cycle and a description of the ABCA4 protein. The current understanding of the genetic pathology of STGD1 is reviewed, including the relationship between STGD1 and similar diseases, genotype-phenotype correlations of ABCA4-associated retinopathy, types of disease-causing genetic variations, geographic/ethnic considerations, and gene therapy. Expert Opinion: In STGD1, ABCA4 gene mutations and gene variation combinations in individuals can be used to predict phenotype, and can be categorized by severity. However, some cases of STGD1 remain unsolved, and disease severity for many variants remains unknown. Increasing our understanding of the genetic pathology of Stargardt disease will drive the development of future therapies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Expert Opinion on Orphan Drugs
Expert Opinion on Orphan Drugs PHARMACOLOGY & PHARMACY-
CiteScore
2.30
自引率
0.00%
发文量
8
期刊介绍: Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.
期刊最新文献
Emerging therapies against Naegleria fowleri Current and emerging therapies for the treatment of leishmaniasis The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022 Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing Overview of genetic testing in Prader-willi syndrome
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1